thalassemia和高凝血能力的情况
Maria Domenica Cappellini1, Ali T Taher2, Irene Motta1,3
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Medicina ad Indirizzo Metabolico, Milan, Italy.
Hematology. American Society of Hematology. Education Program
|December 5, 2025
概括
由于疾病因素和脊髓切除术,β-thalassemia患者面临显著的血栓形成风险. 像luspatercept这样的新药可能有所帮助,但需要专门的指导方针来有效管理血栓形成.
科学领域:
- 血液学 血液学 血液学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塔血症的管理得到了改善,但血栓性事件仍然是主要的并发症.
- 一种高凝血状态是显而易见的,特别是在非输血依赖的β-thalassemia中,由氧化应激和内皮激活等因素驱动.
- 切除术和增加的生存并发症,如心房动,增加了血栓形成的风险.
研究的目的:
- 审查在β-thalassemia中复杂的血栓形成风险因素.
- 讨论新兴疗法,如luspatercept在治疗血栓形成中的潜在作用.
- 强调需要专门的指导方针,用于预防和治疗beta-thalassemia患者的血栓形成.
主要方法:
- 关于beta-thalassemia中血栓形成的研究的文献综述.
- 对疾病特异性促进高凝血能力的因素的分析.
- 评估当前的管理策略和新兴的治疗选择.
主要成果:
- 疾病特异性因素 (ROS,病变性红色素细胞,微粒,自由血红素,内皮活化) 导致高凝血.
- 切除术和心房动是显著的危险因素.
- 卢斯帕特塞普特显示出潜力,但需要进一步调查其在修改血栓形成风险方面的作用.
结论:
- 目前在β-thalassemia中进行的血栓形成管理依赖于一般人群的指导方针,这些指导方针可能不足.
- 需要可靠的数据来制定专门的指导方针,这些指导方针适合贝塔血的独特病理生理学和危险因素.
- 对像luspatercept这样的新药进行进一步的研究对于优化患者护理至关重要.
相关概念视频
01:24Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:30Venous Thrombosis I: Introduction
310
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
310
01:49Multiple Allele Traits
37.9K
The Concept of Multiple Allelism
37.9K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
275
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
275